American Century Companies Inc. grew its holdings in shares of AnaptysBio Inc (NASDAQ:ANAB) by 35.7% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 30,596 shares of the biotechnology company’s stock after purchasing an additional 8,044 shares during the period. American Century Companies Inc. owned approximately 0.13% of AnaptysBio worth $2,174,000 as of its most recent SEC filing.
Other hedge funds have also added to or reduced their stakes in the company. SG Americas Securities LLC purchased a new position in shares of AnaptysBio during the first quarter valued at approximately $173,000. Quantitative Systematic Strategies LLC purchased a new position in shares of AnaptysBio during the second quarter valued at approximately $211,000. Teacher Retirement System of Texas lifted its holdings in shares of AnaptysBio by 28.7% during the second quarter. Teacher Retirement System of Texas now owns 3,335 shares of the biotechnology company’s stock valued at $237,000 after purchasing an additional 743 shares during the last quarter. Xact Kapitalforvaltning AB purchased a new position in shares of AnaptysBio during the second quarter valued at approximately $242,000. Finally, Smith Asset Management Group LP purchased a new position in shares of AnaptysBio during the first quarter valued at approximately $243,000.
Several equities analysts have recently issued reports on the stock. JMP Securities lowered their target price on shares of AnaptysBio from $180.00 to $153.00 and set a “buy” rating for the company in a report on Wednesday, August 15th. Zacks Investment Research lowered shares of AnaptysBio from a “buy” rating to a “hold” rating in a report on Tuesday, August 14th. Cantor Fitzgerald assumed coverage on shares of AnaptysBio in a report on Tuesday, September 4th. They set a “buy” rating and a $124.00 target price for the company. Royal Bank of Canada reiterated a “hold” rating and set a $84.00 target price on shares of AnaptysBio in a report on Wednesday, August 8th. Finally, ValuEngine upgraded shares of AnaptysBio from a “hold” rating to a “buy” rating in a report on Friday, June 1st. Two research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $128.80.
Shares of NASDAQ ANAB opened at $87.77 on Monday. AnaptysBio Inc has a twelve month low of $30.84 and a twelve month high of $134.00. The company has a market capitalization of $2.11 billion, a P/E ratio of -57.74 and a beta of 2.81. The company has a quick ratio of 16.19, a current ratio of 16.19 and a debt-to-equity ratio of 0.01.
AnaptysBio (NASDAQ:ANAB) last announced its quarterly earnings data on Tuesday, August 7th. The biotechnology company reported ($0.57) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.70) by $0.13. sell-side analysts expect that AnaptysBio Inc will post -2.61 earnings per share for the current fiscal year.
AnaptysBio, Inc, a clinical stage biotechnology company, engages in developing antibody product candidates focused on unmet medical needs in inflammation. The company's proprietary anti-inflammatory pipeline includes ANB020, an anti-interleukin-33 antibody for the treatment of moderate-to-severe adult atopic dermatitis, severe adult peanut allergy, and severe adult eosinophilic asthma; ANB019, an anti-interleukin-36R antibody for the treatment of rare inflammatory diseases, including generalized pustular psoriasis and palmo-plantar pustular psoriasis; and a portfolio of checkpoint receptor agonist antibodies for the treatment of certain autoimmune diseases.
Recommended Story: What is a closed-end mutual fund (CEF)?
Want to see what other hedge funds are holding ANAB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AnaptysBio Inc (NASDAQ:ANAB).
Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.